Huyen Tran
Director, Haemophilia Treatment Centre and Head, Haemostasis Thrombosis Unit
University of Arkansas at Fayetteville
faculty
Research Areas
Links
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Huyen Tran's research focuses on the diagnosis and management of complex bleeding and clotting disorders, particularly in the context of haemophilia and thrombosis. Tran has investigated vaccine-induced immune thrombotic thrombocytopenia (VITT), contributing to understanding its diagnosis and management strategies, including approaches used in Australia and New Zealand. This work also extends to understanding thrombosis with thrombocytopenia syndrome following COVID-19 vaccination.
Further research includes evaluating the efficacy and safety of novel prophylactic treatments for individuals with haemophilia A or B, including those with inhibitors. This involves participation in multicenter, randomized phase 3 trials for drugs such as fitusiran and concizumab. Tran's work also addresses the health-related quality of life and health status of adolescent and adult individuals with haemophilia.
Additionally, Tran has been involved in studies related to immune responses to vaccines, comparing innate and adaptive immune responses to COVID-19 mRNA and adenovirus-vectored vaccines. The researcher has also explored rapid detection methods for SARS-CoV-2 RNA in saliva using Cas13 technology.
Metrics
- h-index: 30
- Publications: 220
- Citations: 3,805
Selected Publications
- Endothelial cell activation enhances thromboinflammation in vaccine-induced immune thrombotic thrombocytopenia (2025) DOI
- Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study (2025) DOI
- Radiotheranostic landscape: A review of clinical and preclinical development (2025) DOI
- Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease (2024) DOI
- International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal (2024) DOI
- Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial (2024) DOI
- OpenHands: An Open Platform for AI Software Developers as Generalist Agents (2024) DOI
- Disease and treatment burden of patients with haemophilia entering the explorer6 non‐interventional study (2024) DOI
- Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study (2024) DOI
- Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data (2024) DOI
- Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial (2023) DOI
- Between a rock and a hard place: resumption of oral anticoagulant therapy after intracranial hemorrhage (2023) DOI
- Venous Thromboembolism and Estrogen-Containing Gender-Affirming Hormone Therapy (2023) DOI
- Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1 (2023) DOI
- The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study (2023) DOI
Similar Researchers
Based on overlapping research topics